Table 2
From the following article
Isotype selection in antibody engineering
Jochen G Salfeld
Nature Biotechnology 25, 1369 - 1372 (2007)
doi:10.1038/nbt1207-1369
Table 2. IgG2 and IgG4 isotypes used in therapeutic antibodies on the market or in clinical development
| Ig | Antibody | Target | Stage | Company |
|---|---|---|---|---|
aConfirmed to employ a stabilized IgG4 constant region. | ||||
| IgG2 | ABX-EGF, panitumumab (Vectibix) | EGF-R | Market | Amgen |
| CP-751, 871 | IGF-R | Phase 3 | Pfizer | |
| CP-675, 206 | CTL4 | Phase 3 | Pfizer | |
| AMG 162, denosumab | RANKL | Phase 3 | Amgen | |
| visilizumab (Nuvion) | CD3 | Phase 2/3 | PDL Biopharma | |
| ABX-IL-8 | IL-8 | Phase 2, Discontinued | Abgenix (Amgen) | |
| AMG102 | HGF/SF | Phase 2 | Amgen | |
| CR011-vcMMAE | GPNMB | Phase 1/2 | CuraGen | |
| CP-870893 | CD40 agonist | Phase 1 | Pfizer | |
| CR002 | PDGF-D | Phase 1 | CuraGen | |
| IgG4 | natalizumab (Tysabri) | VLA-4 Integrin (CD49d) | Market | Biogen-Idec |
| Mylotarg, calicheamicin-conjugated antibody | CD33 | Market | Wyeth | |
| CDP 571, Humicade | TNF | Discontinued after phase 3 | Biogen-Idec, UCB | |
| Clenoliximaba | CD4, primatized | Phase 2 completed | Biogen-Idec | |
| Volociximab |  5 1 Integrin | Phase 2 | PDL Biopharma Biogen-Idec | |
| HGS004 | CCR5 | Phase 2 | Human Genome Science | |
| CAT 354 | IL-13 | Phase 2 | AstraZeneca (Medimmune-CAT) | |
| CAT 213 | Eotaxin | Phase 2 | AstraZeneca (Medimmune-CAT) | |
| HuMV833 | VEGF121 VEGF165 | Phase 1 | Academic | |
| 1D09C3 | HLA-DR | Phase 1 | GPC Biotech | |
HOKT3 4 | OKT3 (CD3) | Phase 1, discontinued? | Johnson & Johnson | |
| TGN1412 | CD28 agonistic | Phase 1 discontinued | TeGenero Immuno Therapeutics | |